Nineteen Pharmaceutical Companies Secure New Funding Rounds, Highlighting Advances in mRNA, siRNA, and Targeted Therapies
NanoRibo
mRNA New Vaccine and Drug Developer
Abcuro
ImmunoTherapy Developer
Insight Financing and Investment Database Shows 19 Financing and Investment Events Occurred in the Global Pharmaceutical Field Last Week（2.10~2.16）：
In terms of drug types, the R&D fields that have attracted capital attention includemRNA Therapy, Small Molecules, Monoclonal Antibodies, Cell Therapy, siRNAetc.
Regionally, of the 19 companies that received financing, more than 57% are from the United States.Among them,Aardvark, a company focused on the development of therapies for metabolic diseases, successfully IPOs on Nasdaq, and raised 94 million US dollars.
NanoRibo Completes Series A Financing
NanoRibo Announces Completion of Series A Financing RoundJointly invested by Chengdu BioCity Guosheng Capital and Enran Venture Capital,The proceeds will be mainly used to advance the clinical research of the company's ongoing projects and the development of new projects.
NanoRibo was founded in 2021,Focus on the Development of Novel Vaccines/Drugs in the mRNA FieldAt the end of last year, the company independently developedLyophilized mRNA Respiratory Syncytial Virus（RSV）Vaccine NR2222Received clinical trial implied permission in China. The product not only demonstrates good immunogenicity, efficacy in animal challenge studies, and safety, but also maintains long-term stability during storage and transportation at 2~8°C.
Alternative Bio Inc. Secures Strategic Investment
CrystalMD Announces Strategic Investment in Alternative Bio Inc.; Both Parties Are Advancing Innovative Drug Development Based on the Latter’s Discovered "First-in-Class" Target. This Strategic Investment and Technical Collaboration Will Further Accelerate the Pipeline Development of Alternative Bio Inc.
Alternative Bio Inc. was founded at the end of 2022.Dedicated to regulating cell states by modulating ribosomal and kinase methylation switches, and developing small-molecule targeted drugs for diseases such as cancer and inflammation.。
Currently,Alternative BioIn the research pipeline, there are multiple potential "first-in-class" projects: one is a pan-cancer small molecule inhibitor targeting the RAS-MAPK signaling pathway, particularly RAS mutation-related; another is a novel mechanism small molecule inhibitor in the field of acute pancreatitis treatment.
Abcuro Completes $200 Million Series C Financing
Abcuro Announces Completion of $200 Million Series C Financing RoundLed by New Enterprise Associates (NEA),Other investors include Foresite Capital, RA Capital Management, Bain Capital Life Sciences, etc.Abcuro is a clinical-stage biotechnology company that aims to develop treatments by precisely modulating highly cytotoxic T cells.Autoimmune DiseasesAndCancerInnovative therapies.
Abcuro Developed by the companyUlviprubart is an investigational monoclonal antibody therapy targeting KLRG1., which can selectively eliminate highly cytotoxic T cells while preserving naive T cells, regulatory T cells, and central memory T cells.This round of financing will be used to complete the pivotal Phase II/ⅢPeriod MUSCLE Clinical Trial, which aims to evaluateUlviprubart for the Treatment of Inclusion Body MyositisEfficacy and Safety.
Inclusion Body Myositis is an inflammatory and degenerative muscle disease that typically occurs in elderly individuals, leading to the gradual, painless weakening of muscles. Currently, there are no drugs available for treating myositis.
Aardvark IPO on Nasdaq
Aardvark Therapeutics Announces Initial Public Offering on NASDAQ in the United States（IPO）, at a public offering price of $16.00 per share, with total proceeds expected to be approximately $94.2 million.Aardvark focuses on developing new small-molecule therapies,Treating Metabolic Diseases by Activating Innate Homeostasis Pathways。
Aardvark The company's main candidate product, ARD-101, targets bitter taste receptors expressed in the intestinal lumen.（TAS2Rs）, treatment is currently underwayPrader-Willi Syndrome-Related HyperphagiaPhase III clinical trials. Aardvark is also developing ARD-201, a fixed-dose combination of ARD-101 and a DPP-4 inhibitor, aiming to address some of the limitations of currently marketed GLP-1 therapies for obesity and obesity-related conditions.
Newleos Completes $93.5 Million Series A Financing
Newleos Therapeutics Announces $93.5 Million Series A Financing Led by Goldman Sachs Alternatives, with Additional Investors Including Novo Holdings A/S, Longwood Fund, and DCVC Bio. Newleos is a clinical-stage neuroscience company co-founded by Longwood Fund and experienced leaders in CNS drug development.
Newleos' R&D pipeline coversGeneralized Anxiety, Social Anxiety, Substance Use Disorders, and Cognitive Impairmentand other fields. Its main clinical project NTX-1955 isA GABAA-γ1 Selective Positive Allosteric Modulator, aiming to treat anxiety disorders through different mechanisms of action, has currently entered Phase I trials.
The company's other clinical-stage assets include the selective brain-penetrant V1a antagonist NTX-1472, the TAAR1 partial agonist NTX-2001, and the GABAA-α5 receptor negative allosteric modulator NTX-1511.
Junevity Secures $10 Million in Financing
Junevity Announces $10 Million Seed Funding RoundLed by Goldcrest Capital and Godfrey Capital。Junevity is a biotechnology company developing cell reset therapies., committed to extending lifespan by resetting cellular damage caused by age-related diseases.
Junevity will use this seed funding to strengthen its RESET platform and develop treatments.Type 2 Diabetes, Obesity, and FrailtyRESET platform is a platform that uses large-scale human data and artificial intelligence to identify transcription factor targets and inhibit them using siRNA therapy.
In type 2 diabetes, Junevity's first siRNA therapeutic candidate improved blood glucose control and insulin sensitivity in diabetic mice; in obesity, the company’s second siRNA candidate enhanced adipose tissue metabolism and reduced food intake.
ENA Respiratory Receives $5 Million Investment
ENA Respiratory Announces $5 Million Investment from Flu LabENA is a clinical-stage pharmaceutical company,CorrectIn the development of antiviral host defense immune enhancers，To minimize the impact of viral respiratory infections。
ENA Main Products of the CompanyINNA-051 is a host defense immune enhancer that can locally initiate and enhance the human innate immune response.. As a once-a-week nasal dry powder product, it can be used to reduce the impact of viral respiratory infections and prevent severe complications in high-risk populations.
This round of financing will support the company's planned Phase IIPhase Concept Validation Study to EvaluateEstimate INNA-051In reducing the incidence and duration of symptomatic infections caused by common respiratory virusesSafety and Potential Efficacy.
Bioxodes Secures €2.7 Million in Financing
Bioxodes Announces €2.7 Million Raised from Existing Investors in Series A Extension FinancingBioxodes was founded in 2013.，New therapies for the prevention and treatment of thrombotic and inflammatory diseases are under development.。
Bioxodes The company's main asset, BIOX-101, is a "first-in-class" new drug targeting thrombo-inflammatory diseases. It is synthesized based on a small protein found in tick saliva and aims to...Reduce Secondary Brain Injury Occurring After Hemorrhagic Stroke。
This financing will enable the company to advance BIOX-101 for the treatment of intracerebral hemorrhage.（ICH）Complete results were obtained from the Phase IIa trial BIRCH, and preparations are underway to initiate the potential registrational study of BIOX-101 for the treatment of ICH.ⅡPhase b trial.Bioxodes to Launch Approximately $50 Million Series B Financing in Q2 2025
PulseSight Completes Series A Financing
PulseSight Therapeutics Announces Completion of First Tranche of Series A FinancingPulseSight is an ophthalmic biotechnology company that isDevelopmentA disruptive non-viral vector therapy that aims to protect and improve the vision of patients with retinal diseases through the use of minimally invasive drug delivery technology., mainly focusing on the treatment of age-related macular degeneration（AMD）。
PulseSight Developed by the companyPST-611 is aNon-viral vector therapy,Expressing human transferrin, an efficient iron regulator, proposed for development in the treatment ofDry Age-Related Macular Degeneration (AMD)/Geographic Atrophy (GA)。
Mair Officially Launched and Secured Financing
Torrey Pines Investment and Oost NL, a regional development agency supporting innovation-driven companies, announced the completion of a pre-seed funding round and the launch of Mair Therapeutics.Mair is focused onDevelopment for Neurodegenerative DiseasesThe transformative therapy, theThe company hopes to transform the current state of Parkinson's disease treatment by using cutting-edge computational modeling and discovery technologies, focusing on the rapid identification and development of potential therapies.
Mair Company has gathered a group of entrepreneurs, researchers, and professional investors to accelerate the progress of Parkinson's disease treatment. The company is committed to discovering compounds that can modulate the lysosomal ion channel TMEM175, which maintains optimal conditions for degrading protein aggregates by controlling lysosomal pH.
AudioCure Secures New Round of Financing
AudioCure Pharma Announces New Round of Financing from InfectoPharmAudioCure is committed to developing innovative therapies toTreatment of Hearing Impairment。By protecting and restoring the key cellular players crucial to the hearing process, the company's treatment approach aims to address the root cause of the disease.
Developed by AudioCure AC102 is a drug for the treatment of sudden hearing loss., the product has undergone tolerability and safety testing in humans and is currently in Phase II trials.This round of financing will be mainly used for the further development of AC102.
In addition to the above cases, some other companies also made financing progress last week. Due to space limitations, they will not be introduced one by one here. For more financing information from last week, please click「Read the original text」Go to Insight Database "New Drug Investment and Financing"ModelBlock View.
